CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 1,500 enrolled
Drug / intervention
Not specified
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03281291
NCT03281291N/ACompleted

Molecular Detection and Genotyping of Plasmodium Falciparum Parasites in Young African Children After Immunization With RTS,S/AS01E Malaria Vaccine. An Ancillary Study Protocol to GlaxoSmithKline Phase IIb RTS,S/AS01E Malaria Vaccine Trial (Study Number 204889) Entitled, "Efficacy, Safety and Immunogenicity Study of GSK Biologicals' Candidate Malaria Vaccine (SB257049) Evaluating Schedules With or Without Fractional Doses, Early Dose 4 and Yearly Doses, in Children 5-17 Months of Age.

GlaxoSmithKline·observational·Posted Sep 13, 2017·Updated Jan 23, 2025

In Brief

An observational study for Malaria. Completed, enrolled 1,500 participants across 2 sites in 2 countries.

Detailed Summary

The aim of this study was to evaluate the effectiveness of the RTS,S/AS01E malaria vaccine against both clinical and asymptomatic malaria infections by detecting Plasmodium falciparum (P. falciparum) parasites in blood samples collected from children who received the primary and yearly booster doses of the RTS,S/AS01E vaccine, as part of their participation in the Malaria-094 parent clinical study. The genomic analysis was conducted on parasites found in blood spot samples from children aged 5-17 months, who were vaccinated according to different dosage and schedule regimens as part of the Malaria-094 parent clinical study.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsMalaria
CountriesGhana, Kenya
Collaborators--

Timeline

N/ACompletedFinished
201820192020202120222023202420252026
First PostedSep 13, 2017
Enrollment StartNov 19, 2018
Primary CompletionApr 22, 2022
Study CompletionOct 23, 2023
TodayJul 2, 2026
Enrollment to primary: 3.4 yearsPosted 8.8 years ago